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Abstract
Purpose Anticoagulants may reduce mortality of cancer patients, though the evidence remains controversial. We studied 
the association between different anticoagulants and cancer death.
Methods All anticoagulant use during 1995–2015 was analyzed among 75,336 men in the Finnish Randomized Study of 
Screening for Prostate Cancer. Men with prevalent cancer were excluded. Multivariable Cox regression was performed to 
compare risk of death from any cancer and disease-specific death from 9 specific cancer types between (1) anticoagulant users 
overall and (2) warfarin users compared to anticoagulant non-users and (3) warfarin or (4) low-molecular-weight heparins 
(LMWH) compared to users of other anticoagulants. Medication use was analyzed as time-dependent variable to minimize 
immortal time bias. 1-, 2- and 3-year lag-time analyses were performed.
Results During a median follow-up of 17.2 years, a total of 27,233 men died of whom 8033 with cancer as the primary cause 
of death. In total, 32,628 men (43%) used anticoagulants. Any anticoagulant use was associated with an increased risk of 
cancer death (HR = 2.50, 95% CI 2.37–2.64) compared to non-users. Risk was similar independent of the amount, duration, 
or intensity of use. The risk increase was observed both among warfarin and LMWH users, although not as strong in warfarin 
users. Additionally, cancer-specific risks of death were similar to overall cancer mortality in all anticoagulant categories.
Conclusion Our study does not support reduced cancer mortality among anticoagulant users. Future studies on drug use and 
cancer mortality should be adjusted for anticoagulants as they are associated with significantly higher risk of cancer death.
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Introduction
Venous thromboembolism (VTE) is a clinically important 
complication among patients with malignancies, as the risk 
of VTE is five- to sevenfold in patients with cancer [1, 2]. 
However, especially tumors of pancreas, brain, liver, and Electronic supplementary material The online version of this article (https ://doi.org/10.1007/s1055 2-019-01195 -x) contains 
supplementary material, which is available to authorized users.
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lung are associated with even more risk of VTE and addi-
tionally the risk increases considerably with more advanced 
disease [3]. Cancer patients with deep VTE or pulmonary 
embolism have an eightfold risk of death compared to VTE 
in patients without cancer [4]. Prognosis for cancers patients 
with embolism is fairly poor: 1-year overall survival is only 
38% [5].
The biological rationale of anticoagulants is against can-
cer progression rather than cancer initiation in experimental 
animal studies. Evidence against cancer development is lim-
ited. It has been reported that tissue factor pathway inhibi-
tion has been reported to be relevant in formation of certain 
brain tumors [6]. It has further been suggested that cancer 
cells may activate coagulation through increased expression 
of tissue factor increasing malignant phenotype of cancer 
cells [7].
Significantly more evidence is found on cancer progres-
sion and coagulation cascade as well as anticoagulants; infu-
sion of small amounts of thrombin increases colon cancer 
metastases [8]. Hemophilic mice with Factor VIII deficiency 
are protected against experimentally induced cancer cell 
metastasis [9] and in heterozygous prothrombin-deficient 
mice, metastatic spread is considerably reduced [10]. In 
contrast, in hypercoagulable mice, risk of metastases is 
increased [11]. Concordantly, anticoagulants targeting Fac-
tor Xa and/or thrombin reduce metastases and increases sur-
vival in animal studies [12, 13]. Figure 1 illustrates afore-
mentioned associations reported in the literature.
Vitamin K antagonists (VKA) such as warfarin have 
been promising in some experimental studies [14, 15], but 
a systematic review covering five randomized controlled 
trials (RCTs) (from 1984 to 1997) indicated no evidence 
for improved survival among cancer patients [16]. Results 
of RCTs on low-molecular weight heparins (LMWH) and 
cancer survival are inconsistent and considerable num-
ber of included patients had at least Stage III disease 
possibly affecting the generalizability to less advanced dis-
ease [17–20]. Due to improvements in contemporary cancer 
care since the 1990s, it is unclear whether the results from 
the warfarin RCTs are still applicable. Thus, the effect of 
anticoagulants on risk of cancer death is still under debate.
To date only three cohort/case–control studies of > 300 
patients have assessed warfarin use and risk of cancer-spe-
cific death [21–23] and only one covers other anticoagu-
lant drugs [23]. Due to paucity of studies on this topic, we 
explored the association between all types of anticoagulants 
during 1996–2015 and cancer mortality in the population 
of the Finnish Randomized Study of Screening for Prostate 
Cancer (FinRSPC) [24].
Methods
Study cohort
FinRSPC includes 80,458 men aged 55–67 years at base-
line. After exclusion of prevalent prostate cancer cases, the 
men were randomized during 1996–1999 either to prostate-
specific antigen (PSA) screening at 4-year intervals or to no 
intervention. For this analysis, we further excluded 3,279 
men with previous diagnoses of any other cancer types at 
baseline. In total, 75,336 men were included in the analysis. 
This is demonstrated in Supplementary Fig. 1. Information 
on baseline cancers was obtained from comprehensive Finn-
ish cancer registry, which covers over 90% of cancer cases 
diagnosed in Finland. The follow-up started at randomiza-
tion and continued until death, emigration from Finland or 
1 January 2016, whichever occurred first.
Information on deaths was obtained from the national 
death certificate registry of Statistics Finland, which 
assigns official causes of death based on mandatory death 
certificates. The information included date and immediate, 
Fig. 1  Simplified illustration of 
relation between coagulation 
cascade and cancer metastasis 
and mortality in the literature. 
Additionally, antimetastatic 
effect of anticoagulant drugs 
reported in the literature that 
may decrease cancer mortality
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primary, and contributory causes of death. Only deaths with 
cancer (ICD-10 codes C00-D48) listed as the primary cause 
of death were regarded as cancer deaths.
We also obtained information on conditions that are major 
indications for anticoagulant use: pulmonary embolism 
(ICD-10: I26.0, I26.9), venous thromboembolism (ICD-10: 
I82.0-82.9), and atrial fibrillation (ICD-10: I48) from the 
national care register for health care (HILMO) maintained 
by the National Institute for Health and Welfare, which cov-
ers all hospitals in Finland and records all diagnoses for 
in- and out-patients visits during 1996–2014. Diagnoses 
from primary care are not covered. Additionally, Charlson 
Comorbidity Score [25] was calculated based on diagnoses 
recorded in the HILMO database during 1996–2015.
Information on anticoagulant usage
Information on anticoagulant drug purchases during 
1996–2015 was obtained by linking the study cohort to a 
national medication reimbursement database maintained by 
the Finnish Social Insurance Institution (SII). The record 
linkage was based on the unique personal identification num-
ber assigned to all residents of Finland. Medication usage 
data were available for 75,336 men. As a part of the national 
health insurance that covers all Finnish citizens, SII provides 
reimbursements for purchases of physician-prescribed drugs. 
In Finland, anticoagulant drugs are available only through 
physicians’ prescription. Therefore, the obtained data cover 
all anticoagulant reimbursements in outpatient setting. 
Drugs used during hospital inpatient periods are not covered.
All 14 anticoagulant drugs used in outpatient setting dur-
ing the study period were identified based on their Ana-
tomic Therapeutic Chemical (ATC) codes. These were 
warfarin (B01AA03) and fenindion (B01AA02) as VKAs, 
dalteparin (B01AB04), enoxaparin (B01AB06), and tin-
zaparin (B01AB10) as heparins, clopidogrel (B01AC04), 
dipyridamole (B01AC30), iloprost (B01AC11), and ticlo-
pidine (B01AC05) as aggregation inhibitors, dabigatran 
(B01AE07) and ximelagatran (B01AE05) as direct throm-
bin inhibitors, as well as factor Xa inhibitors rivaroxaban 
(B01AX06), apixaban (B01AF02), and fondaparinux 
(B01AX05). Additionally, we obtained information on cho-
lesterol-lowering drugs, aspirin and other non-steroidal anti-
inflammatory drugs (NSAIDs), antihypertensive drugs, and 
antidiabetic drugs as these may influence survival [26–30].
Statistical analysis
Cox proportional hazards regression was used to calculate 
hazard ratios (HR) and 95% confidence intervals (CIs) for 
cancer death. The follow-up started at the FinRSPC ran-
domization and continued until death or right censoring 
(emigration from Finland or 1 January 2016), whichever 
occurred first. Time metric was years and months since 
the baseline. Validity of proportional hazards assumption 
was tested with an interaction term between follow-up time 
and time-fixed variables. In each case, the interaction term 
was statistically non-significant, confirming the assump-
tion. In addition to general cancer mortality, we explored 
cancer-specific mortality separately for the following can-
cer types: lung, gastric, colorectal, central nervous sys-
tem (CNS), non-Hodgkin lymphoma, hepatic, pancreatic, 
renal, and bladder. Prostate cancer deaths are included in 
general cancer mortality; prostate cancer-specific mortal-
ity has been covered in detail in our previous study [23].
For each man in the study cohort, yearly medication 
purchases were summed to obtain the total annual amount. 
Differences in dosing between different anticoagulants 
were standardized by dividing the total annual milligram 
amount with the standard Defined Daily Dose (DDD) as 
listed by the WHO [31]. Each year with registered antico-
agulant purchases was regarded as a year of usage regard-
less of the amount. Average yearly dosage (intensity of 
use) was estimated by dividing the number of annual doses 
with the number of years of usage. Intensity of use was 
also updated annually as a time-dependent variable.
Anticoagulant use after the FinRSPC randomization 
was analyzed as a time-dependent variable: medication use 
status and cumulative usage were updated for each year of 
follow-up based on annual drug purchases. Men were cat-
egorized as non-users until the year of the first anticoagu-
lant purchase. The status was changed into a user after the 
first purchase and maintained as a user for each year with 
recorded purchases. Men who discontinued anticoagulant 
purchases during the follow-up were categorized as previ-
ous users. In ever-users, both current and previous users 
of anticoagulants were included. Similarly, cumulative 
amount, duration, and average yearly dose were updated 
for each follow-up year according to yearly anticoagulant 
purchases.
In the analysis comparing warfarin users with men using 
other anticoagulant drugs, the men were categorized as war-
farin users each year with recorded warfarin purchases even 
if they had used other types of anticoagulants. Only for years 
with recorded anticoagulant purchases without warfarin use, 
men were considered warfarin non-users. Similar methodol-
ogy was used for comparison between heparin users and men 
using non-heparin anticoagulants.
The main analysis was performed by adjusting Cox 
regression model for age (continuous variable), use of 
other medications (categorical variables), indications for 
anticoagulant usage (categorical variables), and Charlson 
Comorbidity Score (continuous variable) to calculate haz-
ard ratios (HR) and 95% confidence intervals (CIs) for 
cancer deaths. The analysis was performed separately 
for (1) all anticoagulants as a group, (2) warfarin users 
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compared to anticoagulant non-users, (3) warfarin users, 
and (4) LMWH users compared to users of other antico-
agulant drugs.
In order to evaluate impact of timing of anticoagulant 
use, we performed a lag-time analysis, where anticoagulant 
exposure was lagged 1–3 years forward in follow-up time, 
i.e., outcome events were related to 1–3 years earlier.
Additionally, we performed subgroup analyses stratified 
by age at randomization, indication for anticoagulant drug 
use, Charlson Comorbidity Score divided into 3 groups (0 
points, 1–2 points, and 3 or more points), and use of other 
drugs as listed earlier. We also stratified the subgroup analy-
ses by Body Mass Index (BMI), which was available for 
11,345 men of the study population. Statistical significance 
of the effect modification by background variables was 
tested by adding an interaction term between anticoagulant 
use and the tested variable in the Cox regression analysis 
to see whether it improved model fit. p value < 0.05 was 
considered statistically significant.
All statistical analyses were carried out using IBM SPSS 
Statistics 22.0. All statistical tests are two-sided.
Results
Population characteristics
During a median follow-up of 17.2 years, 27,233 men died, 
of whom 8,033 with cancer as the primary cause of death. 
Among men who died from cancer, the median follow-up 
was 11.3 years. A total of 48,103 men were followed up 
until 1 January 2016. In total, 32,628 men (43%) had used 
anticoagulants during 1995–2015. Distribution of cancer 
mortality, numbers of cancer-specific deaths, indications 
for anticoagulant usage, use of other medication, and other 
background variables stratified by anticoagulant user status 
are presented in Table 1.
Risk of cancer death by use of any anticoagulants
Ever-use of any anticoagulant was associated with 
an increased risk of cancer death (HR = 2.50, 95% 
CI 2.37–2.64). The risk was increased for both cur-
rent (HR = 2.20, 95% CI 2.06–2.35) and previous users 
(HR = 2.81, 95% CI 2.64–2.99). The risk increase was 
similar regardless of the amount or intensity of use. The 
increased risk was most pronounced in high-intensity (more 
than 207 DDD/year) usage (HR = 3.09, 95% CI 2.87–3.34). 
When exploring cancer-specific risk of death, the risk was 
elevated for all cancer types, being lowest for hepatic cancer 
and highest for bladder cancer (Table 3).
Risk of cancer death in relation to warfarin use
Compared to other anticoagulants, use of warfarin was 
associated with a significantly lower risk of cancer death 
(HR = 0.45, 95% CI 0.41–0.50). This was observed regard-
less of the amount, duration, or intensity of use (Table 2), the 
risk decrease being most apparent in high-dose (cumulative 
use greater than 1,200 DDD, HR = 0.36, 95% CI 0.31–0.43) 
and high-intensity (more than 193 DDD/year, HR = 0.31, 
95% CI 0.27–0.37) use of warfarin. The risk of cancer-
specific death was significantly lower among warfarin users 
compared to users of other anticoagulants in all cancer types 
(Table 3). 
When using anticoagulant non-users as the reference 
instead of men using other types of anticoagulants, risk for 
cancer death was significantly increased also among warfa-
rin users (HR = 2.34, 95% CI 2.20–2.48). The risk increase 
was considerably elevated for previous users (HR = 3.01, 
95% CI 2.83–3.21) and moderately increased among cur-
rent warfarin users compared to anticoagulant non-users 
(HR = 1.31, 95% CI 1.19–1.43). Warfarin use was associated 
with an elevated risk of cancer death compared to anticoagu-
lant non-users regardless of amounts, duration, or intensity 
of use (Table 2). Risk of cancer-specific death was elevated 
for all cancer types (Table 3).
Risk of cancer death related to heparin use
In total, 12,326 men used LMWH during the study period 
(69% had used 80 DDD or less). LMWH users compared 
to non-LMWH anticoagulant users were at significantly 
higher risk of cancer death (HR 2.04, 95% CI 1.90–2.20) 
(Table 2). Risk increase was especially high for high dose 
(more than 80 DDD), use for 2 year or longer, and high-
intensity (more than 60 DDD/year) usage. Low dose (40 
DDD or less) was not associated with increased risk of can-
cer death. Conversely, in 3-year lag-time the risk association 
was reversed to be lower in LMWH users compared to users 
of other anticoagulant drugs (HR = 0.86, 95% CI 0.77–0.95). 
Cancer mortality was significantly elevated for all examined 
cancer types with the exception of central nervous system 
cancers, where the risk increase was statistically non-sig-
nificant (Table 3). The most pronounced risk increase was 
observed for pancreatic and colorectal cancer death.
Lag‑time analysis
Any use of anticoagulants compared to non-users was 
associated with an increased risk of cancer death in 1-year, 
2-year, and 3-year lag-time analyses. The risk slightly atten-
uated with longer lag-time but remained elevated. Risk of 
cancer-specific death remained elevated in 3-year lag-time 
for all cancer types (Table 3).
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When comparing warfarin users to anticoagulant non-
users, the risk remained elevated although slightly attenu-
ated over all lag times up to 3 years (Table 3).
Risk decrease for overall cancer death observed in the 
main analysis disappeared in the lag-time analyses com-
paring warfarin users to users of other anticoagulants 
(Table 2). The same was observed for cancer-specific risks 
of death, and the risk decrease remained statistically sig-
nificant for only non-Hodgkin lymphomas in 1- and 2-year 
lag-time models (Table 3).
Subgroup analysis
Among all anticoagulant users, significant effect modifica-
tion was observed for age at randomization, indication for 
anticoagulant use (excluding atrial fibrillation), for use of 
statins or antidiabetic drugs, and Charlson Comorbidity 
Score (p < 0.001 for each). Also BMI modified the effect 
statistically significantly (p = 0.010). The effect modifi-
cation was most pronounced for VTE diagnosis, the risk 
Table 1  Characteristics of the study population stratified by anticoagulant user status
NSAID non-steroidal anti-inflammatory drug
a Warfarin and LMWH user status not mutually exclusive. 6,119 men used both warfarin and LMWH during the study period
b Information on BMI was available only for 11,345 men. Value 27.6 was the median and was used to divide into two groups of equal size
Anticoagulant user status
No anticoagulation Warfarina LMWHa Non-warfarin or 
LMWH anticoagu-
lants
Total n of deaths Median 
age at 
death
n of men in the study population 42.708 17.826 12.326 8.595
Overall cancer mortality/10,000 
person years
n of cancer deaths
75 54 81 46
 Overall 4,766 (11.2%) 1,549 (8.7%) 1,733 (14.1%) 654 (7.6%) 8.033 72
 Lung cancer 1,404 (3.3%) 380 (2.1%) 351 (2.8%) 213 (2.5%) 1.739 71
 Gastric cancer 203 (0.7%) 52 (0.3%) 76 (0.6%) 24 (0.3%) 327 71
 Colorectal cancer 414 (1.0%) 144 (0.8%) 233 (1.9%) 49 (0.6%) 764 72
 Central nervous system cancers 112 (0.3%) 32 (0.2%) 27 (0.2%) 21 (0.2%) 182 69
 Non-Hodgkin lymphomas 125 (0.3%) 64 (0.4%) 65 (0.5%) 18 (0.2%) 244 74
 Hepatic cancer 292 (0.7%) 79 (0.4%) 67 (0.5%) 34 (0.4%) 441 71
 Pancreatic cancer 432(1.0%) 118 (0.7%) 195 (1.6%) 45 (0.5%) 733 71
 Renal cancer 124 (0.3%) 51 (0.3%) 72 (0.6%) 20 (0.2%) 239 72
 Bladder cancer 87 (0.2%) 52 (0.3%) 66 (0.5%) 18 (0.2%) 195 73
Recorded diagnoses of
 Pulmonary embolisms 112 (0.3%) 661 (3.7%) 634 (5.1%) 59 (0.7%)
 Venous thromboembolism 23 (0.1%) 205 (1.2%) 233 (1.9%) 12 (0.1%)
 Atrial fibrillation 953 (2.2%) 9,174 (51.5%) 3,833 (31.1%) 508 (0.6%)
Charlson Comorbidity Score
 0 points 24,979 (58.5%) 6,354 (35.6%) 4,133 (33.5%) 3,879 (45.1%)
 1–2 points 12,669 (29.7%) 6,226 (34.9%) 4,566 (37.0%) 3,020 (35.1%)
 3 or more points 5,060 (11.8%) 5,246 (29.4%) 3,627 (29.4%) 1,696 (19.7%)
Use of other medication
 Statin users 16,307 (38.2%) 11,613 (65.1%) 7,827 (63.5%) 7,060 (82.1%)
 Aspirin users 4,218 (9.9%) 3,666 (20.6%) 2,542 (20.6%) 4,266 (49.6%)
 NSAID users 34,574 (80.1%) 16,016 (89.8%) 11,865 (96.3%) 7,883 (91.7%)
 Antihypertensive drug users 27,860 (65.2%) 17,055 (95.7%) 10,698 (86.8%) 7,835 (91.2%)
 Antidiabetic drug users 6,300 (14.8%) 4,237 (23.8%) 3,154 (25.6%) 2,215 (25.8%)
Body Mass Index (BMI)b
 < 27.6 3,442 (8.1%) 1,078 (6.0%) 958 (7.8%) 604 (7.0%)
 ≥ 27.6 2,780 (6.5%) 1,603 (9.0%) 1,265 (10.3%) 700 (8.1%)
882 Cancer Causes & Control (2019) 30:877–888
1 3
Table 2  Multivariable and lag-time hazard ratios (95% CI) related to cancer-specific deaths
n of deaths Multivariable-adjusted 1-year lag-time 2-year lag-time 3-year lag-time
Any anticoagulant compared to anticoagulant non-users
 None 4.766 Ref. Ref. Ref. Ref.
 Ever-users 3.267 2.50 (2.37–2.64) 2.20 (2.08–2.32) 1.73 (1.64–1.83) 1.67 (1.57–1.77)
Amount of anticoagulant use
 ≤ 200 DDD 1.348 2.28 (2.14–2.43) 1.94 (1.82–2.08) 1.52 (1.42–1.64) 1.54 (1.43–1.66)
 200–1,100 DDD 1.046 2.74 (2.54–2.96) 2.41 (2.23–2.61) 1.90 (1.74–2.06) 1.77 (1.62–1.93)
 > 1,100 DDD 873 2.84 (2.62–3.09) 2.64 (2.42–2.87) 2.06 (1.88–2.26) 1.87 (1.69–2.07)
Duration of anticoagulant use
 ≤ 2 year 1.867 2.47 (2.33–2.62) 2.12 (1.99–2.25) 1.61 (1.51–1.72) 1.57 (1.47–1.68)
 3–5 years 663 2.64 (2.42–2.89) 2.38 (2.17–2.61) 1.91 (1.73–2.11) 1.78 (1.60–1.98)
 6 or more years 737 2.50 (2.29–2.74) 2.34 (2.13–2.56) 1.99 (1.80–2.19) 1.91 (1.72–2.11)
Intensity of anticoagulant use
 ≤ 100 DDD/year 1.234 2.23 (2.09–2.38) 1.91 (1.78–2.05) 2.53 (1.42–1.65) 1.52 (1.40–1.64)
 97–207 DDD/year 929 2.50 (2.31–2.70) 2.16 (1.99–2.35) 1.78 (1.63–1.94) 1.78 (1.63–1.95)
 > 207 DDD/year 1.104 3.09 (2.87–3.34) 2.84 (2.62–3.06) 2.07 (1.90–2.25) 1.83 (1.67–2.01)
Warfarin compared to anticoagulant non-users
 None 4.766 Ref. Ref. Ref. Ref.
 Ever-users 1.549 2.34 (2.20–2.48) 2.06 (1.94–2.19) 1.73 (1.63–1.85) 1.66 (1.55–1.77)
Amount of warfarin use
 ≤ 307 DDD 713 2.61 (2.39–2.84) 2.25 (2.06–2.46) 1.74 (1.58–1.91) 1.71 (1.55–1.89)
 307–1200 DDD 482 2.29 (2.07–2.55) 2.19 (1.97–2.44) 1.85 (1.66–2.07) 1.76 (1.57–1.98)
 > 1200 DDD 354 2.04 (1.81–2.30) 2.07 (1.84–2.33) 1.81 (1.60–2.05) 1.70 (1.49–1.95)
Duration of warfarin use
 ≤ 2 year 720 2.45 (2.25–2.67) 2.18 (1.99–2.38) 1.70 (1.55–1.87) 1.67 (1.51–1.84)
 3–7 years 504 2.37 (2.14–2.63) 2.23 (2.00–2.47) 1.83 (1.63–2.04) 1.67 (1.48–1.87)
 8 or more years 325 2.21 (1.95–2.50) 2.17 (1.91–2.46) 1.96 (1.72–2.24) 2.00 (1.74–2.30)
Intensity of warfarin use
 ≤ 120 DDD/year 701 2.34 (2.14–2.55) 2.09 (1.90–2.29) 1.68 (1.52–1.87) 1.65 (1.49–1.84)
 120–193 DDD/year 446 1.75 (1.58–1.95) 1.77 (1.59–1.98) 1.56 (1.39–1.75) 1.58 (1.40–1.78)
 > 193 DDD/year 402 1.53 (1.37–1.70) 1.75 (1.58–1.95) 1.71 (1.54–1.91) 1.66 (1.48–1.86)
Warfarin compared to other anticoagulant drugs
 Non-warfarin anticoagulant users 1.718 Ref. Ref. Ref. Ref.
 Warfarin users 1.549 0.45 (0.41–0.50) 1.00 (0.91–1.09) 1.09 (0.99–1.21) 1.03 (0.92–1.14)
 Amount of warfarin use
 ≤ 307 DDD 713 0.68 (0.59–0.78) 1.23 (1.07–1.40) 1.12 (0.96–1.31) 1.13 (0.96–1.33)
 307–1200 DDD 482 0.39 (0.33–0.45) 0.94 (0.83–1.07) 1.10 (0.96–1.26) 0.99 (0.86–1.15)
 > 1200 DDD 354 0.36 (0.31–0.43) 0.88 (0.77–1.01) 1.07 (0.92–1.24) 0.98 (0.83–1.15)
Duration of warfarin use
 ≤ 2 year 720 0.58 (0.50–0.66) 1.17 (1.03–1.33) 1.11 (0.96–1.28) 1.09 (0.93–1.27)
 3–7 years 504 0.40 (0.34–0.46) 0.92 (0.81–1.04) 1.05 (0.92–1.20) 0.90 (0.78–1.04)
 8 or more years 325 0.40 (0.34–0.47) 0.92 (0.79–1.06) 1.14 (0.98–1.33) 1.17 (0.99–1.39)
Intensity of warfarin use
 ≤ 120 DDD/year 701 0.71 (0.62–0.81) 1.23 (1.07–1.40) 1.14 (0.98–1.33) 1.04 (0.88–1.24)
 120–193 DDD/year 446 0.42 (0.36–0.49) 0.99 (0.86–1.13) 1.05 (0.91–1.22) 0.99 (0.84–1.17)
 > 193 DDD/year 402 0.31 (0.27–0.37) 0.86 (0.76–0.98) 1.09 (0.96–1.25) 1.04 (0.91–1.20)
LMWH compared to other anticoagulant drugs
 Non-LMWH anticoagulant users 1.534 Ref. Ref. Ref. Ref.
 LMWH users 1.733 2.04 (1.90–2.20) 1.57 (1.45–1.70) 1.02 (0.93–1.12) 0.86 (0.77–0.95)
Amount of warfarin use
 ≤ 40 DDD 497 1.09 (0.98–1.20) 0.99 (0.89–1.11) 0.81 (0.72–0.91) 0.73 (0.63–0.83)
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increase being strongest among those who had recorded 
diagnosis of VTE (Fig. 2).
When comparing warfarin to other types of anticoagu-
lants, effect modification was observed for indication of anti-
coagulant use, Charlson Comorbidity Score and for NSAID, 
antihypertensive and antidiabetic drug use. Otherwise, the 
risk of overall death was similar independent of background 
variables (Fig. 3).
Among LMWH users compared to use of other antico-
agulant drugs, effect modification was observed for VTE, 
atrial fibrillation, Charlson Comorbidity Score, and use of 
antihypertensive drugs (Supplementary Fig. 2)
Sensitivity analysis
Since the data included cancer deaths but not cancer diag-
noses, we performed a sensitivity analysis comparing crude 
median survival times to end of year 2014 for the studied 
cancer types for anticoagulant non-user, anticoagulant users, 
and users of warfarin only and LMWH only. Median follow-
up ranged from 0 to 4.5 years, being lowest for lung and 
hepatic cancer and highest for renal and bladder cancer and 
non-Hodgkin lymphomas. These data are provided in Sup-
plementary Table.
Discussion
Anticoagulant use was associated with an increased risk 
of overall and cancer-specific cancer death independent of 
duration, amounts, or intensity of use. The risk increase pre-
vailed although slightly attenuated in all lag-time analyses. 
The risk association was modified by indications of usage 
and by comorbidities; especially diagnosis of VTE greatly 
modified the risk association, although number of recorded 
VTE diagnoses was relatively low. For specific cancer types, 
the risk of cancer-specific death was increased for all cancer 
types, especially for bladder cancer.
The risk associations were similar when comparing users 
of warfarin to anticoagulant non-users for both overall and 
cancer-specific risk of death. When comparing warfarin 
users to users of other anticoagulant drugs, the risk was con-
siderably lower in the non-lagged analysis but in the lag-time 
analyses the risk associations were similar. The same was 
observed for the risk of cancer-specific death. Thus, the tim-
ing of warfarin use modified the risk associations, especially 
when comparing to anticoagulant non-users. Strongest effect 
modification was observed by diagnosis of atrial fibrillation, 
Charlson Comorbidity Score, and use of antihypertensive 
drugs.
All anticoagulant sub-types were associated with an 
increased risk of cancer death. However, risk of cancer 
death among warfarin users compared to other anticoagu-
lants was much lower but still elevated compared to non-
users although warfarin is not recommended for treatment 
of cancer-induced thrombi. A possible explanation for the 
lower risk among users of warfarin compared to other anti-
coagulants in the non-lagged analysis is most likely due to 
an increased risk associated with indication of anticoagulant 
use, especially LMWH use which was associated with signif-
icantly high risk of overall cancer death and cancer-specific 
death in the non-lagged analysis. LMWH is recommended 
for management of VTE in patients with cancer, as the likeli-
hood of VTE recurrence may be lower when using this drug 
group in cancer patients [32]. Current Finnish guidelines 
for thromboprophylaxis in cancer patients recommend treat-
ment with LMWH for 3–12 months or permanently. The vast 
majority (69%) of the LMWH users in our study cohort used 
less than 80 DDD of LMWH, equaling a duration of use for 
less than 3 months.
Despite promising results in experimental animal stud-
ies [6–13], we found no decreased risk of cancer death 
associated with either warfarin or other anticoagulant 
drugs. On the contrary, the risk of cancer death is signifi-
cantly increased. Out of previous epidemiological studies, 
our study is only comparable to O’Rorke et al. [20], as the 
other two studies [19, 21] covered only prostate cancer 
Table 2  (continued)
n of deaths Multivariable-adjusted 1-year lag-time 2-year lag-time 3-year lag-time
 40–80 DDD 276 1.59 (1.40–1.82) 1.28 (1.10–1.48) 0.95 (0.79–1.13) 0.90 (0.74–1.10)
 > 80 DDD 960 4.73 (4.34–5.15) 3.38 (3.06–3.74) 1.70 (1.48–1.96) 1.23 (1.02–1.47)
Duration of warfarin use
 ≤ 1 year 1.173 1.80 (1.66–1.94) 1.46 (1.34–1.59) 0.96 (0.87–1.06) 0.83 (0.74–0.93)
 2 or more years 560 3.00 (2.71–3.32) 2.00 (1.77–2.27) 1.29 (1.09–1.52) 0.98 (0.79–1.21)
Intensity of warfarin use
 ≤ 40 DDD/year 580 1.12 (1.01–1.23) 1.01 (0.91–1.11) 0.82 (0.73–0.92) 0.75 (0.65–0.85)
 40–60 DDD/year 198 1.66 (1.43–1.93) 1.35 (1.14–1.61) 1.07 (0.87–1.32) 0.97 (0.77–1.23)
 > 60 DDD/year 955 4.83 (4.43–5.26) 3.40 (3.07–3.75) 1.62 (1.41–1.87) 1.15 (0.96–1.38)
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Table 3  Multivariable and lag-time hazard ratios (95% CI) related to cancer-specific deaths
n of deaths Multivariable-adjusted 1-year lag-time 2-year lag-time 3-year lag-time
Any anticoagulant compared to anticoagulant non-users
 All cancers
  Non-user 4.766 Ref. Ref. Ref. Ref.
  Ever-user 3.267 2.50 (2.37–2.64) 2.20 (2.08–2.32) 1.73 (1.64–1.83) 1.67 (1–57–1.77)
 Cancer type
  Lung cancer 799/1,404a 2.19 (1.97–2.42) 1.89 (1.70–2.10) 1.55 (1.39–1.74) 1.53 (1.36–1.71)
  Gastric cancer 124/203a 3.03 (2.33–3.96) 2.93 (2.24–3.85) 2.13 (2.60–2.84) 2.00 (1.48–2.70)
  Colorectal cancer 350/414a 3.51 (2.96–4.16) 3.01 (2.53–3.58) 2.15 (1.80–2.58) 1.80 (1.49–2.18)
  Central nervous system cancers 70/112a 3.23 (2.25–4.64) 3.02 (2.09–4.36) 1.59 (1.06–2.39) 1.28 (0.83–1.99)
  Non-Hodgkin lymphomas 119/125a 2.91 (2.16–3.93) 2.53 (1.87–3.42) 1.97 (1.44–2.68) 1.69 (1.23–2.33)
  Hepatic cancer 149/292a 1.64 (1.30–2.06) 1.43 (1.13–1.82) 1.32 (1.03–1.69) 1.37 (1.06–1.78)
  Pancreatic cancer 301/431a 2.90 (2.44–3.46) 2.10 (1.75–2.52) 1.48 (1.22–1.80) 1.51 (1.23–1.84)
  Kidney cancer 115/124a 3.08 (2.28–4.17) 2.35 (1.73–3.19) 1.75 (1.27–2.41) 1.75 (1.26–2.43)
  Bladder cancer 108/87a 4.99 (3.58–6.96) 4.44 (3.19–6.20) 2.87 (2.04–4.04) 2.67 (1.89–3.77)
Warfarin compared to anticoagulant non-users
 All cancers
  No anticoagulant use 4.766 Ref. Ref. Ref. Ref.
  Warfarin ever-use 1.549 2.34 (2.20–2.48) 2.06 (1.94–2.19) 1.73 (1.63–1.85) 1.66 (1.55–1.77)
 Cancer type
  Lung cancer 380/1,404b 2.01 (1.79–2.26) 1.74 (1.54–1.97) 1.51 (1.33–1.72) 1.40 (1.22–1.60)
  Gastric cancer 52/203b 2.89 (2.14–3.90) 2.56 (1.87–3.51) 2.02 (1.45–2.82) 1.85 (1.30–2.63)
  Colorectal cancer 144/414b 3.10 (2.56–3.76) 2.68 (2.20–3.26) 2.03 (1.65–2.49) 1.82 (1.47–2.25)
  Central nervous system cancers 32/112b 2.68 (1.77–4.05) 2.43 (1.58–3.74) 1.39 (0.87–2.23) 1.02 (0.61–1.73)
  Non-Hodgkin lymphomas 64/125b 2.73 (1.96–3.81) 2.48 (1.78–3.46) 2.04 (1.45–2.86) 1.88 (1.32–2.67)
  Hepatic cancer 79/292b 1.47 (1.13–1.91) 1.51 (1.16–1.96) 1.42 (1.08–1.87) 1.53 (1.15–2.02)
  Pancreatic cancer 118/431b 2.47 (2.02–3.01) 1.80 (1.46–2.22) 1.55 (1.25–1.93) 1.54 (1.22–1.93)
  Renal cancer 51/124b 2.73 (1.95–3.83) 2.12 (1.50–2.99) 1.57 (1.09–2.25) 1.40 (0.95–2.06)
  Bladder cancer 52/87b 5.29 (3.69–7.60) 4.45 (3.09–6.40) 2.91 (2.00–4.24) 2.62 (1.78–3.88)
Warfarin compared to other anticoagulant drugs
 All cancers
  Non-warfarin anticoagulant users 1.718 Ref. Ref. Ref. Ref.
  Warfarin users 1.549 0.45 (0.41–0.50) 1.00 (0.91–1.09) 1.09 (0.99–1.21) 1.03 (0.92–1.14)
 Cancer type
  Lung cancer 380/419c 0.63 (0.52–0.75) 1.09 (0.91–1.30) 1.13 (0.93–1.38) 1.00 (0.81–1.24)
  Gastric cancer 52/72c 0.35 (0.20–0.61) 1.11 (0.70–1.77) 1.29 (0.78–2.12) 0.86 (0.49–1.51)
  Colorectal cancer 144/206c 0.37 (0.27–0.51) 0.86 (0.65–1.15) 1.02 (0.74–1.40) 1.10 (0.77–1.56)
  Central nervous system cancers 32/38c 0.43 (0.23–0.83) 1.40 (0.77–2.55) 1.08 (0.52–2.26) 1.00 (0.44–2.27)
  Non-Hodgkin lymphomas 64/55c 0.48 (0.29–0.78) 1.79 (1.14–2.82) 1.75 (1.07–2.87) 1.64 (0.96–2.81)
  Hepatic cancer 70/79c 0.45 (0.29–0.69) 0.82 (0.53–1.25) 0.97 (0.62–1.53) 1.06 (0.65–1.71)
  Pancreatic cancer 118/183c 0.34 (0.23–0.48) 0.79 (0.57–1.10) 1.26 (0.88–1.80) 1.16 (0.79–1.69)
  Renal cancer 51/64c 0.31 (0.18–0.56) 0.71 (0.43–1.18) 0.77 (0.43–1.36) 0.60 (0.32–1.14)
  Bladder cancer 52/56c 0.41 (0.23–0.72) 0.98 (0.59–1.63) 1.16 (0.66–2.03) 1.40 (0.79–2.51)
LMWH compared to other anticoagulants
 All cancers
  Non-LMWH anticoagulants 1.534 Ref. Ref. Ref. Ref.
  LMWH 1.733 2.04 (1.90–2.20) 1.57 (1.45–1.70) 1.02 (0.93–1.12) 0.86 (0.77–0.95)
 Cancer type
  Lung cancer 351/448d 1.46 (1.26–1.69) 1.10 (0.93–1.30) 0.67 (0.54–0.82) 0.61 (0.48–0.77)
  Gastric cancer 48/76d 3.39 (2.30–4.98) 3.19 (2.14–4.75) 1.31 (0.82–2.09) 1.16 (0.69–1.96)
  Colorectal cancer 233/117d 3.60 (2.84–4.56) 2.75 (2.15–3.50) 1.70 (1.29–2.23) 1.06 (0.77–1.45)
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deaths. O’Rorke et al. additionally included lung, colo-
rectal, and breast cancer-specific deaths. They reported 
increased risk of lung cancer death for pre-diagnostic but 
no risk increase for post-diagnostic warfarin use. For colo-
rectal cancer, an increased risk of death was associated 
with post-diagnostic, but not with pre-diagnostic use. Our 
results for lung and colorectal cancer death and warfarin 
use are similar. Since we did not have sufficient data to 
divide anticoagulant use into pre- and post-diagnostic use, 
our results are not completely comparable, but both studies 
suggest that among lung and colorectal cancer patients, 
warfarin use is not associated with decreased mortality.
This study has several strengths: a large population-based 
cohort with a median follow-up of 17.2 years and detailed 
register-based information on anticoagulant use preventing 
recall bias. We were able to stratify use of anticoagulants by 
amounts (DDD), duration, and intensity of use, and to com-
pare anticoagulant users with non-users, as well as warfarin 
users to users of other anticoagulants in addition to antico-
agulant non-users. We also compared LMWH users to users 
Table 3  (continued)
n of deaths Multivariable-adjusted 1-year lag-time 2-year lag-time 3-year lag-time
  Central nervous system cancers 27/43d 1.10 (0.66–1.84) 0.73 (0.41–1.31) 0.65 (0.30–1.40) 0.76 (0.32–1.79)
  Non-Hodgkin lymphomas 65/54d 2.38 (1.62–3.50) 2.17 (1.44–3.26) 1.87 (1.20–2.94) 1.79 (1.09–2.93)
  Hepatic cancer 67/82d 1.46 (1.04–2.05) 0.84 (0.56–1.25) 0.43 (0.25–0.73) 0.45 (0.25–0.80)
  Pancreatic cancer 195/106d 3.57 (2.78–4.58) 1.91 (1.46–2.50) 1.05 (0.76–1.46) 0.81 (0.56–1.18)
  Renal cancer 72/43d 3.21 (2.14–4.81) 2.81 (1.83–4.32) 1.72 (1.07–2.77) 1.46 (0.87–2.44)
  Bladder cancer 66/42d 2.80 (1.85–4.25) 1.78 (1.16–2.73) 0.95 (0.57–1.59) 0.67 (0.37–1.21)
Comparison between (1) anticoagulant users and non-users, (2) warfarin users and anticoagulant non-users, (3) warfarin users and users of other 
anticoagulants, and (4) LMWH users and user of other anticoagulants
Statistically significant results are bolded
a Deaths among anticoagulant users/deaths among non-users
b Deaths among warfarin users/deaths among anticoagulant non-users
c Deaths among warfarin users/deaths among users of other anticoagulants
d Deaths among LMWH users/death among users of other anticoagulants
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of other anticoagulant drugs. Additionally, we were able to 
perform lag-time analyses to estimate the impact of timing 
of anticoagulant use. We were also able to study several 
cancer types to evaluate cancer-specific risk of death. For 
several cancer types, risk of cancer-specific death among 
anticoagulant users has not been reported earlier in epide-
miological studies. Most published clinical trials on this 
topic have involved breast cancer and lung cancer patients. 
Prostate cancer was not separately analyzed in this study, as 
we have previously covered it in detail [21]. In that study, 
we reported that post-diagnostic use of anticoagulants was 
associated with 1.6-fold and use of warfarin 1.5-fold risk 
of prostate cancer death when compared to anticoagulant 
non-users.
This study also has certain limitations. For many cancer 
types, the number of deaths was relatively low. We had lim-
ited information on BMI, only for 11,345 men (15%), which 
may influence cancer mortality and cause confounding [33]. 
BMI was assessed only in the subgroup analysis. Addition-
ally, we did not have information on smoking, which has 
been associated with increased risk of death in many cancer 
types [34]. However, we were able to adjust for Charlson 
Comorbidity Score. We did not have information on dietary 
factors and physical activity which are linked to cancer 
prognosis [35]. Misclassification in cause of death on death 
certificates has been reported which could bias the associa-
tion away from null [36]. Another limitation is that drug use 
during hospital inpatient periods is not covered. However, if 
a person has had a clear indication for anticoagulant usage, 
i.e., not only prophylaxis, the drug use is continued after 
hospitalization and is visible in the data used in this study. 
Furthermore, our study was not randomized and hence the 
comparability of the users and non-users was uncertain, 
with potential for confounding by indication. Additionally, 
our results might not be applicable to younger population, 
women, or non-Caucasian ethnicities, as this cohort covered 
only Finnish men aged 55–67 at baseline.
In a population-based setting, use of anticoagulants is 
associated with an increased risk of cancer death. The risk 
increase is likely caused by increased likelihood of thrombo-
sis in cancer patients and the resulting treatment. In warfarin 
users, the risk increase was smaller compared to users of 
LMWH, but the risk was nevertheless increased compared 
to non-users of anticoagulants.
Conclusion
Anticoagulants as a group are associated with an increased 
risk of cancer death. Our study does not support reduced 
cancer mortality among anticoagulant drug users. For future 
studies exploring use of any drug group and cancer mortal-
ity, we recommend adjusting for use of anticoagulant drugs 
as this drug group is rarely adjusted for and is associated 
with significantly higher risk of cancer death. Addition-
ally, we recommend exploring new oral anticoagulants and 
cancer mortality as they have now been in use for several 
years, but epidemiological studies on the topic are virtually 
non-existing.
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